Is there a difference in gait function of women treated with a ceramic resurfacing compared to women who received a conventional THA?
Amy Maslivec et al. compared PROMs and gait analysis from 15 female patients treated with unilateral ceramic hip resurfacing (H1® Anatomic Ceramic Hip Resurfacing, Embody Orthopaedic) and 15 matched female patients treated with unilateral total hip replacement.
The H1® ceramic hip resurfacing device is currently undergoing a Clinical Investigation approved by the UK Health Research Authority and the researchers also used records from healthy controls, to assess the difference in gait function between the ceramic hip resurfacing (cHR) and total hip replacement patients.
The comparisons revealed that ceramic hip resurfacing allowed female patients to achieve higher metabolic equivalents (MET) scores and maximum walking speeds (MWS) compared to women treated with conventional total hip replacement.
MET score for the cHR group improved significantly from a mean score of 5 pre-operatively to 11.2 post-operatively.
With an increase of 33% compared to their pre-operative level, MWS for women treated with ceramic hip resurfacing were 6.8±0.3 km/hr, with no significant difference compared to healthy controls (7±0.5 km/hr).
When walking at a faster speed of 6 km/hr, female patients treated with ceramic hip resurfacing were able to move the same way as the healthy controls, with the same step length of 79 cm.
Despite the limitations of this study, early results suggest possible near normal gait function and activity levels for women who received the ceramic hip resurfacing.
The H1® Anatomic Ceramic Hip Resurfacing made of BIOLOX®delta is in clinical investigation in the EU and UK by Embody Orthopaedic Ltd. The H1® is investigational device tested in a clinical study approved by MHRA and NHS, respectively. The H1® Anatomic Ceramic Hip Resurfacing is not approved by any authorities and not commercially available.
This product is not cleared or approved by the FDA for distribution in the United States. The H1® (Embody Ltd.) ceramic hip resurfacing device is undergoing a Clinical Investigation approved by the UK Health Research Authority. For product, safety, and risk information, always refer to the labeling of the legal manufacturer.
📚 Maslivec A, Halewood C, Clarke S, Cobb J. Hip resurfacing arthroplasty in women: A novel ceramic device enables near normal gait function [published online ahead of print, 2023 May 18]. Gait Posture. 2023;103:166-171. doi:10.1016/j.gaitpost.2023.05.015